{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:39:50Z","timestamp":1794490790907,"version":"4.9.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T00:00:00Z","timestamp":1562630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Malignant peritoneal mesothelioma (MPeM) is a rare cancer for which no standard systemic chemotherapy has been established. While cisplatin plus pemetrexed, the standard treatment for malignant pleural mesothelioma (MPlM), is usually used for MPeM, its efficacy remains unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively reviewed the medical charts of MPeM patients who had received cisplatin plus pemetrexed as first-line chemotherapy between January 2001 and July 2016 at the National Cancer Center Hospital. Patients received cisplatin 75 mg\/m2 and pemetrexed 500 mg\/m2 on day1, repeated every 3 weeks until progressive disease, unacceptable toxicities or patient\u2019s refusal to continue.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 29 MPeM patients received cisplatin plus pemetrexed. Median progression-free survival and overall survival were 7.1 months (95% CI: 4.8\u20139.3) and 15.4 months (95% CI: 9.5\u201321.2), respectively. Among 16 patients with measurable lesions, the response rate was 38%. Incidences of grade 3\/4 leukopenia, neutropenia, anemia and thrombocytopenia were 21%, 17%, 14% and 3%, respectively. Non-hematological toxicities were mild, and there were no treatment-related deaths.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Cisplatin plus pemetrexed, showing consistent efficacy with MPlM, can be recommended as first-line treatment for unresectable MPeM patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyz104","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T17:36:48Z","timestamp":1561052208000},"page":"1004-1008","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma"],"prefix":"10.1093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-2910","authenticated-orcid":false,"given":"Yusuke","family":"Nagata","sequence":"first","affiliation":[{"name":"Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan"},{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, 3-19-18 Nishishinbashi, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Sawada","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan"},{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, 3-19-18 Nishishinbashi, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Takashima","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Shoji","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Honma","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Iwasa","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsushi","family":"Amano","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, 3-19-18 Nishishinbashi, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kato","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Hamaguchi","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Shimada","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Saruta","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, 3-19-18 Nishishinbashi, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,9]]},"reference":[{"key":"2019122810174181700_hyz104C1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/CEJ.0b013e3282f0c0a2","article-title":"US mesothelioma patterns 1973-2002: indicators of change and insights into background rates","volume":"17","author":"Teta","year":"2008","journal-title":"Eur J Cancer Prev"},{"key":"2019122810174181700_hyz104C2","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/annonc\/mdl345","article-title":"Epidemiology of peritoneal mesothelioma: a review","volume":"18","author":"Boffetta","year":"2007","journal-title":"Ann oncol."},{"key":"2019122810174181700_hyz104C3","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/oem.51.12.804","article-title":"Malignant mesothelioma: attributable risk of asbestos exposure","volume":"51","author":"Spirtas","year":"1994","journal-title":"Occup Envirom Med"},{"key":"2019122810174181700_hyz104C4","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J clin Oncol"},{"key":"2019122810174181700_hyz104C5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/14737140.2017.1340157","article-title":"First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma","volume":"17","author":"Fujimoto","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"2019122810174181700_hyz104C6","first-page":"215","article-title":"Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases","volume":"34","author":"Nakano","year":"2014","journal-title":"Anticancer Res."},{"key":"2019122810174181700_hyz104C7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/030089161109700105","article-title":"Systemic chemotherapy with Pemetrexed and cisplatin for malignant mesothelioma: a single institution experience","volume":"97","author":"Lainakis","year":"2011","journal-title":"Tumori."},{"key":"2019122810174181700_hyz104C8","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/jjco\/hyq083","article-title":"The efficacy of frontline platinum-based combination chemoptherapy in malignant peritoneal mesothelioma","volume":"40","author":"Kim","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"2019122810174181700_hyz104C9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","article-title":"Malignant peritoneal mesothelioma - Results from the international expanded access program using pemetrexed alone or in combination with a platinaum agent","volume":"64","author":"Carteni","year":"2009","journal-title":"Lung Cancer"},{"key":"2019122810174181700_hyz104C10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of expanded access program","volume":"7","author":"Janne","year":"2005","journal-title":"Clin Lung Cancer"},{"key":"2019122810174181700_hyz104C11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.rmed.2009.07.019","article-title":"Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany","volume":"104","author":"Reck","year":"2010","journal-title":"Respir Med"},{"key":"2019122810174181700_hyz104C12","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/CLEP.S105396","article-title":"Mesothelioma in the United states: a Surveilance, Epidemiology, and End Results(SEER)-Medicare investigation of treatment patterns and overall survival","volume":"8","author":"Jennifer","year":"2016","journal-title":"Clin Epidemiol"},{"key":"2019122810174181700_hyz104C13","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/annonc\/mdi187","article-title":"Second-line (post-study) chemotherapy received by patients treated in phase III trial of pemetrexed plus cisplatin alone in malignant pleural mesothelioma","volume":"16","author":"Manegolds","year":"2005","journal-title":"Ann Oncol"},{"key":"2019122810174181700_hyz104C14","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomized, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet Oncol"},{"key":"2019122810174181700_hyz104C15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"2019122810174181700_hyz104C16","doi-asserted-by":"crossref","first-page":"S1883","DOI":"10.1016\/j.jtho.2017.09.634","article-title":"A phase II study of nivolumab: a mulicenter, open-label, single arm srudy in malignant pleural mesothelioma (MERIT)","volume":"12","author":"Goto","year":"2017","journal-title":"J Thorac Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/49\/11\/1004\/31630318\/hyz104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/49\/11\/1004\/31630318\/hyz104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,28]],"date-time":"2019-12-28T10:17:54Z","timestamp":1577528274000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/49\/11\/1004\/5530220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,9]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,7,9]]},"published-print":{"date-parts":[[2019,12,18]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyz104","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,7,9]]}}}